NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-07-23
Reading WGS? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a turnaround situation with medium confidence. WGS is currently loss-making and has shown weak recent financial performance, but it operates in a sector with potential tailwinds.
The market seems to have priced in a low expectations gap, indicating that investors are not overly optimistic about WGS's near-term recovery. Valuation is at a premium compared to peers, suggesting that the market is cautious but not overly pessimistic.
Management has mixed priorities, including achieving positive adjusted net income and updating revenue guidance, which has been lowered. Recent financial performance has been weak, and while the miss probability is low, the company has a history of erratic earnings surprises.
The future of WGS hinges on whether it can reverse course and raise guidance in the next quarter. Additionally, the performance of sector bellwethers like TMO, DHR, and IDXX will be crucial in determining if the Healthcare sector momentum continues to support WGS.
In the next 1 to 3 years, WGS's performance will depend on management's ability to stabilize earnings and the overall health of the Healthcare sector. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Earnings results will show if the company can recover from the recent earnings miss.
Confirms one read:Q2 earnings show a profit or meet expectations after the earnings miss.
Confirms the other:Q2 earnings did not meet expectations again. This raises worries about financial health.
Why it matters: The new revenue guidance shows the company can carry out its plans.
Confirms:Q2 2026 revenue reported between $110 million and $112 million.
Disproves:Q2 2026 revenue falls below $110 million.
Why it matters: Growth in these areas is crucial for the company's overall revenue health.
Confirms:Exome and genome revenue growth reported above 15% year over year.
Disproves:Exome and genome revenue growth reported below 5% year over year.
Why it matters: The company previously lowered its revenue guidance. A new update could signal better performance.
Confirms:Revenue guidance updated to $490M or higher for 2026.
Disproves:Revenue guidance remains at or below $475M for 2026.
Why it matters: This goal matters for the company's financial recovery. It also affects investor trust.
Confirms:The company reports adjusted net income for the quarter. This shows improvement.
Disproves:There are continued losses in adjusted net income. This shows ongoing financial struggles.
Why it matters: Positive adjusted net income helps long-term growth. It also builds trust with investors.
Confirms:Adjusted net income reported as positive for Q2 2026.
Disproves:Adjusted net loss reported for Q2 2026.
Why it matters: Keeping up volume growth shows strong demand and good operations.
Confirms:Exome and genome volume grew by at least 30% compared to last year.
Disproves:Exome and genome volume growth falls below 30% year-over-year.
